Table 3 Comparison between clinical features of double positivity SSc specific autoantibody group, and cohort of patients with single autoantibody positivity.
From: Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes
Double antibody group | Comparator group | Clinical features | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arthritis | ILD | PAH | SRC | Cardiac | Myositis | ||||||||
n | p | n | p | n | p | n | p | n | p | n | p | ||
U1 RNP and ATA | 6 (29%) | 15 (68%) | 1 (9%) | 0 | 0 | 4 (19%) | |||||||
U1RNP | 14 (18%) | 1 | 38 (50%) | 0.136 | 12 (16%) | 0.287 | 1 (1%) | 1 | 2 (3%) | 1 | 12 (16%) | 0.744 | |
ATA | 28 (10%) | 0.025 | 213 (79%) | 0.382 | 12 (4%) | 1 | 17 (6%) | 0.622 | 20 (7%) | 0.378 | 10 (4%) | 0.013 | |
U1RNP and ACA | 2 (25%) | 2 (25%) | 4 (50%) | 0 | 0 | 3 (37%) | |||||||
U1RNP | 14 (18%) | 1 | 38 (50%) | 0.267 | 12 (16%) | 0.039 | 1 (1%) | 1 | 2 (3%) | 1 | 12 (16%) | 0.148 | |
ACA | 23 (6%) | 0.087 | 43 (11%) | 0.233 | 56 (15%) | 0.022 | 6 (2%) | 1 | 10 (3%) | 1 | 3 (1%) | 0.001 | |
U1RNP and ARA | 0 | 2 (50%) | 0 | 1 (25%) | 1 (25%) | 0 | |||||||
U1RNP | 14 (18%) | 0.311 | 38 (50%) | 1 | 12 (16%) | 1 | 1 (1%) | 0.098 | 2 (3%) | 0.144 | 12 (16%) | 1 | |
ARA | 4 (3%) | 1 | 64 (45%) | 1 | 15 (10%) | 1 | 34 (24%) | 1 | 4 (3%) | 0.131 | 5 (3%) | 1 | |
U1 RNP and PmScl | 1 (33%) | 2 (66%) | 0 | 0 | 0 | 3 (100%) | |||||||
U1RNP | 14 (18%) | 1 | 38 (50%) | 1 | 12 (16%) | 1 | 1 (1%) | 1 | 2 (3%) | 1 | 12 (16%) | 0.006 | |
PmScl | 7 (13%) | 1 | 27 (50%) | 1 | 3 (6%) | 1 | 3 (6%) | 1 | 1 (2%) | 1 | 21 (39%) | 0.069 | |
ATA and ACA | 0 | 3 (75%) | 0 | 0 | 0 | 1 (25%) | |||||||
ATA | 28 (10%) | 1 | 213 (79%) | 1 | 12 (4%) | 1 | 17 (6%) | 1 | 20 (7%) | 1 | 10 (4%) | 0.153 | |
ACA | 23 (6%) | 1 | 43 (11%) | 0.006 | 56 (15%) | 1 | 6 (2%) | 1 | 10 (3%) | 1 | 3 (1%) | 0.041 | |
ACA and PmScl | 1 (25%) | 1 (25%) | 0 | 0 | 0 | 1 (25%) | |||||||
ACA | 23 (6%) | 0.227 | 43 (11%) | 0.385 | 56 (15%) | 1 | 6 (2%) | 1 | 10 (3%) | 1 | 3 (1%) | 0.04 | |
PmScl | 7 (13%) | 0.457 | 27 (50%) | 0.612 | 3 (6%) | 1 | 3 (6%) | 1 | 1 (2%) | 1 | 21 (39%) | 1 | |
ACA and U3RNP | 0 | 1 (50%) | 0 | 0 | 0 | 0 | |||||||
ACA | 23 (6%) | 1 | 43 (11%) | 0.216 | 56 (15%) | 1 | 6 (2%) | 1 | 10 (3%) | 1 | 3 (1%) | 1 | |
U3RNP | 3 (6%) | 1 | 12 (24%) | 0.456 | 13 (26%) | 1 | 5 (10%) | 1 | 6 (12%) | 1 | 9 (18%) | 1 | |
PmScl and Ku | |||||||||||||
PmScl | 7 (13%) | 0.268 | 27 (50%) | 1 | 3 (6%) | 1 | 3 (6%) | 1 | 1 (2%) | 1 | 21 (39%) | 1 | |
Ku | 1 (20%) | 1 | 2 (40%) | 1 | 0 | 1 | 0 | 1 | 1 (20%) | 1 | 2 (40%) | 1 | |
U1RNP and U3 RNP | |||||||||||||
U1RNP | 14 (18%) | 1 | 38 (50%) | 0.675 | 12 (16%) | 0.271 | 1 (1%) | 0.142 | 2 (3%) | 0.206 | 12 (16%) | 0.585 | |
U3RNP | 3 (6%) | 0.084 | 12 (24%) | 0.643 | 13 (26%) | 0.654 | 5 (10%) | 0.511 | 6 (12%) | 0.569 | 9 (18%) | 0.575 | |
ATA and Ku | |||||||||||||
ATA | 28 (10%) | 0.289 | 213 (79%) | 1 | 12 (4%) | 0.138 | 17 (6%) | 1 | 20 (7%) | 1 | 10 (4%) | 1 | |
Ku | 1 (20%) | 1 | 2 (40%) | 0.196 | 0 | 0.375 | 0 | 1 | 1 (20%) | 1 | 2 (40%) | 0.464 | |
